Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling

Rina Kanda, Akihiko Kawahara, Kosuke Watari, Yuichi Murakami, Kahori Sonoda, Masashi Maeda, Hideaki Fujita, Masayoshi Kage, Hidetaka Uramoto, Carlota Costa, Michihiko Kuwano, Mayumi Ono

Research output: Contribution to journalArticlepeer-review

121 Citations (Scopus)


EGF receptor (EGFR) kinase inhibitors, including gefitinib and erlotinib, exert potent therapeutic efficacy in non-small cell lung cancers harboring EGFR-activating mutations. However, most patients ultimately develop resistance to these drugs. Here, we report a novel mechanism of acquired resistance to EGFR tyrosine kinase inhibitors and the reversal of which could improve clinical outcomes. In erlotinib-resistant lung cancer cells harboring activating EGFR mutations that we established, there was increased expression of Src, integrin β1, a2, and a5 along with enhanced cell adhesion activity. Interestingly, RNAi-mediated silencing of integrin β1 restored erlotinib sensitivity and reduced activation of Src and Akt after erlotinib treatment. Furthermore, Src silencing inhibited Akt phosphorylation and cell growth, with this inhibitory effect further augmented by erlotinib treatment. Increased expression of integrin β1, α5, and/or α2 was also observed in refractory tumor samples from patients with lung cancer treated with erlotinib and/or gefitinib. Together, our findings identify the integrin β1/Src/Akt signaling pathway as a key mediator of acquired resistance to EGFR-targeted anticancer drugs.

Original languageEnglish
Pages (from-to)6243-6253
Number of pages11
JournalCancer Research
Issue number20
Publication statusPublished - Oct 15 2013
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling'. Together they form a unique fingerprint.

Cite this